KANGFANG

About us

Position:HOME > About us > News

BioWorld: Akeso's Checkpoint-Blocking MAb Draws MSD in $200M Agreement

Date:2015-12-09 14:49:00 Views:
Share
bioworld logo.jpg
By 
Cornelia Zou 
Staff Writer 

Wednesday, December 9, 2015

HONG KONG – Three-year old Chinese novel monoclonal antibody (MAb) developer Akeso Biopharma Inc. has signed a $200 million deal with MSD China, out-licensing its first compound. The deal comes on the heels of closing a $20 million series A financing funded by local investors.

Read at http://www.bioworld.com/content/akesos-checkpoint-blocking-mab-draws-msd-200m-agreement